Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 14/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30897109 | 1.00 | ADCY5 (0.45) | ADCY5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8885246 | 1.00 | ADCY5 (0.45) | ADCY5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8885990 | 0.84 | ADCY5 (0.46) | ADCY5AHCY | |
| SCHEMBL8660508 | 0.83 | ADCY5 (0.64) | ADCY5AHCY | |
| SCHEMBL27350557 | 0.83 | ADCY5 (0.64) | ADCY5AHCY | |
| SCHEMBL9147328 | 0.83 | ADCY5 (0.64) | ADCY5AHCY | |
| SCHEMBL30969135 | 0.82 | ADCY5 (0.54) | ADCY5PDE4DAHCY | |
| SCHEMBL7592748 | 0.82 | ADCY5 (0.54) | ADCY5PDE4DAHCY | |
| SCHEMBL5994923 | 0.82 | ADCY5 (0.54) | ADCY5PDE4DAHCY | |
| SCHEMBL5994918 | 0.82 | ADCY5 (0.54) | ADCY5PDE4DAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107859-A1 | CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230382932-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382932-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382932-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| EP-3765474-B1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3765474-B1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210230196-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-10968242-B2 | Cyclopentane-based modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968242-B2 | Cyclopentane-based modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3765474-A1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200102334-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-20200102334-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-20190284216-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284216-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2019175776-A1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019175776-A1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20090281126-A1 | Organic Compounds | NOVARTIS AG | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230196-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | ADCY5 1603/4885PDE4A 30/4885PDE4B 63/4885 |
| US-20190284216-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | ADCY5 1603/4885PDE4A 30/4885PDE4B 63/4885 |
| US-20230382932-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | ADCY5 1603/4885PDE4A 30/4885PDE4B 63/4885 |
| US-20200102334-A1 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | ADCY5 1603/4885PDE4A 30/4885PDE4B 63/4885 |
| US-10968242-B2 | Cyclopentane-based modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | ADCY5 1603/4885PDE4A 30/4885PDE4B 63/4885 |
| US-20090281126-A1 | Organic Compounds | CYP3A43, CYP3A4, CYP2C19 | ADCY5 3307/4885PDE4A 2848/4885PDE4B 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.